CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/04/2023
Voltar para busca
Dado oficial do USPTO
BIOHAVEN PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
03/04/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
22/06/2021
Data de registro
25/01/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/01/2022
Última transação
03/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Primeiro uso
2020-03-00
Primeiro uso no comércio
2020-03-00
Código do desenho
3
Tipo de titular
99
Localização do titular
Road Town, Tortola, VG
Examinador
CLIFFORD, MEGAN
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the stylized wording "BIOHAVEN PHARMACEUTICALS", with two outlined hexagon shapes positioned above the letter "I" and one outlined hexagon shape positioned below the letter "I", and the wording "PHARMACEUTICALS" appearing in smaller print below the wording "BIOHAVEN".
Titulares e representantes
Titulares
Biohaven Therapeutics Ltd.
Biohaven Therapeutics Ltd.
Representantes
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicated and pharmaceutical preparationsboth prescription and over-the-counterfor use in connection with humans and animalsfor the treatment of central nervous system disordersneurologic illnessespsychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemiapost-stroke recoverysevere intracranial atherosclerosiscarotid endarterectomycardiac bypasscerebral vasculitisreversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuriespost- intracranial hemorrhage recoverytraumatic brain injuryspinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseasesAlzheimer's disease (AD)Amyotrophic Lateral Sclerosis (ALS)Huntington's diseaseLewy body dementiafrontotemporal dementiavascular dementiaParkinson's diseasecognitive impairment of agingprogressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathiesglaucomadiabetic retinopathyischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of painopioid sparing analgesiacancer painchronic neuropathic painperipheral neuropathylow back pain in the nature of failed back surgery syndromeradiculopathy in the nature of sciaticadiabetic peripheral neuropathypost-herpetic neuralgiachemotherapy induced neuropathy and other medication induced neuropathiescomplex regional pain syndromefibromyalgiachronic post-operative paincluster thoracotomyphantom limbstump neuroma; pharmaceutical preparations for the treatment of headache and facial painheadachemigrainechronic daily headachecluster headachetrigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseasesbreath holding in Rett syndromedystoniasdysphagiagait abnormalitiesbulbar function in Amyotrophic Lateral Sclerosis (ALS)pseudobulbar affectlevodopa-induced dyskinesias in Parkinson's diseaseagitation in Alzheimer's disease (AD)disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsyprecision medicine for the adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorderstreatment resistant depressionPost Traumatic Stress Disorder (PTSD) in the nature of hyperarousalsubstance abuse disordersaddiction disordersObsessive Compulsive Disorder (OCD)hoardingtrichotillomaniaeating disordersGeneralized Anxiety Disorder (GAD)adjustment disorderspanic disordermajor depressive episodebipolar disorder in the nature of manic and depressive episodesdysthymiacyclothymiapsychotic disordersschizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disordersspinocerebellar ataxiaFriedriech's ataxiamultisystem atrophyessential tremor; pharmaceutical preparations for the treatment of hearing disorderstinnitusdeliriumsleep disordersparasomniaslearning disordersAttention Deficit Disorder (ADD)Pervasive Developmental Disorders (PDD)Asperger's syndromeautismmenopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancermonotherapy and adjunctive use
Classe 42
Pharmaceutical research and development in the fields of headachefacial painimpulse control disordersneurological disordersneurodegenerative disordersconsultation provided in conjunction therewith
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/04/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/04/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/04/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/04/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
23/06/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
25/01/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/11/2021
PUBO
PUBLISHED FOR OPPOSITION
09/11/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/10/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/09/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/09/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/09/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/09/2021
GNRT
NON-FINAL ACTION E-MAILED
10/09/2021
CNRT
NON-FINAL ACTION WRITTEN
10/09/2021
DOCK
ASSIGNED TO EXAMINER
08/09/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/09/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/09/2021
NWAP
NEW APPLICATION ENTERED
25/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BIOHAVEN PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.